| 1 |
31770593 | The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. | 2020 Jan |
1 |
| 2 |
31128178 | Insight into ponatinib resistance mechanisms in rhabdomyosarcoma caused by the mutations in FGFR4 tyrosine kinase using molecular modeling strategies. | 2019 Aug 15 |
1 |
| 3 |
28069043 | FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. | 2017 Jan 9 |
1 |
| 4 |
28094372 | Theoretical studies on FGFR isoform selectivity of FGFR1/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations. | 2017 Feb 1 |
2 |
| 5 |
26574622 | Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations. | 2016 |
1 |
| 6 |
25317566 | DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors. | 2015 Jan 16 |
2 |
| 7 |
25219510 | Structural analysis of the human fibroblast growth factor receptor 4 kinase. | 2014 Nov 11 |
2 |
| 8 |
25465127 | Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4. | 2014 Dec 2 |
5 |
| 9 |
24124571 | Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534). | 2013 |
6 |